Although centralized HER2 testing may help identify these individuals, the recruitment of such patients is likely to be prohibitively slow if HER2‐positivity rates are as low as those encountered, especially in pancreatic cancer. This evidence concerns the gene ERBB2 and pancreatic neoplasm.